GE HealthCare opens free AI training program

AuntMinnie.com staff writers

May 19, 2026

GE HealthCare (GEHC) is making more than 20 hours of AI education available at no cost through its HelloAI program.

The curriculum covers AI integration in radiology and ultrasound, data handling, responsible adoption frameworks, and how clinicians communicate AI to patients, according to the company. It is designed for clinicians, researchers, administrators, and leaders and is available in an on-demand online format. A separate one-hour HelloAI Foundations introductory course is also available free of charge.

GEHC noted that physician use of AI has more than doubled since 2023 to 81%, according to the American Medical Association, but that training has lagged adoption. The company said that it tops the U.S. Food and Drug Administration's list of AI-enabled device authorizations, with 100 clearances to date over four years.

To learn more, visit helloaiprofessional.com, the company said.

HOPPR launches mammography vision-language model

May 19, 2026

Overview of the study design, including data collection, radiomics model construction, and biologic interpretation. (A) The primary cohort for model development and evaluation in the training and internal test sets includes 168 patients with colorectal cancer (CRC) from center 1 (Fudan University Shanghai Cancer Center), whereas external testing was performed using data from 85 patients from centers 2 (Huashan Hospital, Fudan University) and 3 (Zhongshan Hospital, Fudan University). For model interpretation, RNA sequencing (RNA-seq) data from 18 patients with CRC in center 1 and single-cell data from 35 patients from the Gene Expression Omnibus (GEO) database are incorporated. Mismatch repair (MMR) protein expression, obtained from pathologic reports in electronic medical records (EMRs), was used to identify patients with consensus molecular subtype 1 (CMS1) CRC. Tissue microarrays (TMAs) from surgically obtained CRC tissues were analyzed for immunohistochemical staining of caudal-type homeobox 2 (CDX2), 5-hydroxytryptamine receptor 2B (HTR2B), FERM domain containing 6 (FRMD6), and zinc finger E-box binding homeobox 1 (ZEB1), and the results were subsequently entered into an online classification tool that assigned patients to CMS2, 3, or 4 subtypes. (B) Radiomics workflow for CMS4 prediction. Lesions were manually delineated on T2-weighted imaging (T2WI) and contrast-enhanced (CE) T1-weighted imaging (T1WI), followed by radiomics feature extraction. Feature selection and model development were performed in the training set using machine-learning algorithms with fivefold cross-validation for model selection, and the final model was evaluated in the internal and external test sets using receiver operating characteristic (ROC) curve analysis. (C) Transcriptomic interpretation workflow. Using the radiomics-predicted CMS4 classification, bulk RNA sequencing (RNA-seq) data were used to perform differential expression analysis between predicted CMS4 and non-CMS4 groups, followed by pathway enrichment analyses to assess biologic relevance. Public single-cell RNA sequencing data from the Gene Expression Omnibus database were then used for cell-type–level interrogation to support interpretation of the associated pathways.

MRI-based ML model shows promise in colorectal cancer subtyping

May 19, 2026

Viz.ai launches pulmonary AI suite

May 14, 2026

OmniMRI in the context of reporting.

ISMRM: Researchers highlight advancements in MRI foundation models

May 14, 2026

HOPPR launches mammography vision-language model

By AuntMinnie.com staff writers

The model was trained on more than 200,000 mammography studies from multiple U.S. sites.

May 19, 2026

MRI-based ML model shows promise in colorectal cancer subtyping

By Amerigo Allegretto

A machine-learning model based on MRI radiomics achieved high performance in predicting colorectal cancer subtypes.

May 19, 2026

Overview of the study design, including data collection, radiomics model construction, and biologic interpretation. (A) The primary cohort for model development and evaluation in the training and internal test sets includes 168 patients with colorectal cancer (CRC) from center 1 (Fudan University Shanghai Cancer Center), whereas external testing was performed using data from 85 patients from centers 2 (Huashan Hospital, Fudan University) and 3 (Zhongshan Hospital, Fudan University). For model interpretation, RNA sequencing (RNA-seq) data from 18 patients with CRC in center 1 and single-cell data from 35 patients from the Gene Expression Omnibus (GEO) database are incorporated. Mismatch repair (MMR) protein expression, obtained from pathologic reports in electronic medical records (EMRs), was used to identify patients with consensus molecular subtype 1 (CMS1) CRC. Tissue microarrays (TMAs) from surgically obtained CRC tissues were analyzed for immunohistochemical staining of caudal-type homeobox 2 (CDX2), 5-hydroxytryptamine receptor 2B (HTR2B), FERM domain containing 6 (FRMD6), and zinc finger E-box binding homeobox 1 (ZEB1), and the results were subsequently entered into an online classification tool that assigned patients to CMS2, 3, or 4 subtypes. (B) Radiomics workflow for CMS4 prediction. Lesions were manually delineated on T2-weighted imaging (T2WI) and contrast-enhanced (CE) T1-weighted imaging (T1WI), followed by radiomics feature extraction. Feature selection and model development were performed in the training set using machine-learning algorithms with fivefold cross-validation for model selection, and the final model was evaluated in the internal and external test sets using receiver operating characteristic (ROC) curve analysis. (C) Transcriptomic interpretation workflow. Using the radiomics-predicted CMS4 classification, bulk RNA sequencing (RNA-seq) data were used to perform differential expression analysis between predicted CMS4 and non-CMS4 groups, followed by pathway enrichment analyses to assess biologic relevance. Public single-cell RNA sequencing data from the Gene Expression Omnibus database were then used for cell-type–level interrogation to support interpretation of the associated pathways.

Viz.ai launches pulmonary AI suite

By AuntMinnie.com staff writers

The suite integrates acute and chronic pulmonary workflows in a single platform.

May 14, 2026

ISMRM: Researchers highlight advancements in MRI foundation models

Standardization is key to effective large-scale studies.

May 14, 2026

OmniMRI in the context of reporting.

Brainomix, Boehringer expand pulmonary fibrosis imaging AI partnership

By AuntMinnie.com staff writers

Platform measures lung features associated with interstitial lung diseases (ILD).

May 12, 2026

Women's Imaging MinnieCast, Episode 8: New NCCN guidance on AI and breast cancer risk

By Amerigo Allegretto

Bethany Niell, MD, PhD, talks new guidance on breast cancer screening by the NCCN, which includes image-based AI risk assessment.

May 8, 2026

Minnie Cast Thumbnail (4) (1)

AMA CPT Editorial Panel pushes emerging imaging tools proposals

By AuntMinnie.com staff writers

Proposals for new AI malignancy risk score, quantitative CT tools deferred.

May 7, 2026

Imaging fellow tries vibe coding to solve radiology challenges

Vibe coding outside the radiology department led to exploring real-world use cases.

May 6, 2026

Kaustav Bera, MD, discussed the rise of the radiologist-developer with AuntMinnie. In June, Bera will complete an abdominal imaging fellowship at Case Western Reserve University and plans to continue as an abdominal imager at Case Western.

ACR, SIIM approve AI practice parameter, launch Assess-AI registry

By AuntMinnie.com staff writers

The ACR and SIIM have approved an AI practice parameter, and the ACR has launched the Assess-AI registry.

May 5, 2026

Artificial Intelligence Ai 400

MRI reveals how hidden muscle fat increases risk to heart, metabolism

By Kate Madden Yee

The results suggest that MRI exams could "augment traditional risk factor screening," researchers noted.

May 5, 2026

SimonMed expands AI-enabled imaging platform nationwide

By AuntMinnie.com staff writers

The expansion introduces three new offerings: Calcium Score+, CT Bone Density, and MR Lumbar Spine+.

May 4, 2026

DL model outperforms breast density in measuring women's cancer risk

By Amerigo Allegretto

A DL model outperformed breast density in estimating future breast cancer risk.

May 4, 2026

Breast Mammo Computer 400 (3)

Page 1 of 408